| Document |
Document Title |
|
WO/2010/063069 |
The present invention relates to compounds that are useful as metal ligands and which either contain a molecular recognition moiety or can be bound to a molecular recognition moiety and methods of making these compounds. Once the compoun...
|
|
WO/2009/089482 |
Substituted pyridoindoles for incorporation in pharmaceutical compositions employed in the treatment of various diseases correspond to formula (I) wherein R1 is H or optionally substituted alkyl; R2, R3, R4 are each independently selecte...
|
|
WO/2008/122115 |
This invention relates to compounds for the inhibition of histone deacetylase. More particularly, the invention provides for compounds of formula compounds of the Formula (I) and N-oxides, hydrates, solvates, pharmaceutically acceptable ...
|
|
WO/2007/138307 |
A sulfur-containing acid removal process for deacidifying a crude oil and/or crude oil distillate containing sulfur-containing acids comprising the steps of: (a) contacting the crude oil and/or crude oil distillate containing sulfur-cont...
|
|
WO/2007/138307 |
A sulfur-containing acid removal process for deacidifying a crude oil and/or crude oil distillate containing sulfur-containing acids comprising the steps of: (a) contacting the crude oil and/or crude oil distillate containing sulfur-cont...
|
|
WO/2007/134958 |
There are presented compounds of the formula (I) wherein R1, R2, R3 and R4 are as defined in the description and claims, or a pharmaceutically acceptable salt thereof, which are active adenosine A2B receptor antagonists and useful in the...
|
|
WO/2007/108742 |
The present invention relates to new compounds of formula I, or salts, solvates or solvated salts thereof, wherein Q, R1, R2, R3, R4 and n are defined as in claim 1, processes for their preparation and to new intermediates used in the pr...
|
|
WO/2007/087684 |
The present invention relates generally to substituted benzofurans, benzothiophenes, and indoles and their use as tubulin polymerisation inhibitors.
|
|
WO/2005/116020 |
Objects of the present invention are the compounds of formula (I), their pharmaceutically acceptable salts, enantiomeric forms, diastereoisomers and racemates, the preparation of the above-mentioned compounds, medicaments containing them...
|
|
WO/2005/100370 |
The present invention refers to new compounds derived from artesunate salts with quinolines represented by the general formula (I) where X is represented by the general formula (II) and Y is represented by the general formula (III) depen...
|
|
WO/2005/075422 |
The invention relates to a process for the manufacture of an 1,2,4-triazol-1-yl compound of the formula [A], or a salt thereof, wherein each of R3 and R4 is hydrogen or lower alkyl, said process comprising reacting a hydrazine compound o...
|
|
WO/2005/070896 |
The invention relates to a method for producing ionic liquids consisting first in reacting an ionic liquid with an alkylate, a hydrogencarbonate, a carbonate, a carboxylate or a hydroxide and, afterwards in neutralising with an acid. The...
|
|
WO/2005/070923 |
A crystalline polymorph of a bislulfate salt of a thrombin receptor antagonist compound, which exhibits a powder x-ray diffraction profile substantially the same as that shown in FIG. 1, or which exhibits a differential scanning calorimt...
|
|
WO/2005/068404 |
The invention relates to a method for the distillation of ionic liquids. According to said method, in one step the pressure is set to a value below the ambient pressure and in a subsequent step, the ionic liquid is heated to a temperatur...
|
|
WO/2005/040121 |
The present invention relates to compounds of formula (I), that are novel VR1 antagonists useful in treating pain, inflammatory thermal hyperalgesia, urinary incontinence, or bladder overactivity.
|
|
WO/2005/037954 |
Disclosed is a compound represented by formula 1: wherein each of A, X, Y, Y’, and Y’’ has the same meaning as described herein. When used in an organic light emitting device, the compound represented by formula 1 has at least one ...
|
|
WO/2005/030712 |
A series of compounds represented by the structural formulas and pharmaceutically acceptable isomers, salts, solvates and polymorphs thereof are disclosed. Also disclosed are pharmaceutical compositions containing said compounds and thei...
|
|
WO/2005/030712 |
A series of compounds represented by the structural formulas and pharmaceutically acceptable isomers, salts, solvates and polymorphs thereof are disclosed. Also disclosed are pharmaceutical compositions containing said compounds and thei...
|
|
WO/2005/023235 |
The invention aims at providing novel low-molecular compounds which have G-CSF-like activities and can substitute for G-CSF preparations. The invention relates to G-CSF-like agonists containing as the active ingredient benzyl alcohol der...
|
|
WO/2005/019183 |
Disclosed is a method for producing purified 1,3-substituted imidazolium salts of general formula (I) by reacting a 1,3-substituted imidazolium salt of general formula (II) with a strong base at a temperature ranging between 20 and 250 Â...
|
|
WO/2005/016890 |
Compounds of Formula (I), are novel VR1 antagonists that are useful in treating pain, inflammatory thermal hyperalgesia, urinary incontinence and bladder overactivity.
|
|
WO/2005/014583 |
An azole derivative of formula (I) having a fluorovinyl moiety or a pharmaceutically acceptable salt thereof is superior to the conventional antifungal drugs in antifungal activity against a wide spectrum of pathogenic fungi, and has adv...
|
|
WO/2004/089914 |
The invention relates to benzenesulphonamide derivatives of formula (I), methods and intermediate products for production thereof and use of said compounds, or means comprising said compounds for the control of undesired plants and for t...
|
|
WO/2004/083208 |
The present invention relates to novel substituted piperidine and piperazine derivatives as melanocortin-4 receptor (MC-4R) modulators. MC-4R agonists of the invention can be used for the treatment of disorders and diseases such as obesi...
|
|
WO/2004/080973 |
Compounds having the formula (I) (I), are useful for inhibiting protein kinases. Also disclosed are methods of making the compounds, compositions containing the compounds, and methods of treatment using the compounds.
|
|
WO/2004/080974 |
Disclosed is an ionic liquid purification method for preparing high purity ionic liquids which can be used as solvents for organic, inorganic and biochemical reactions or as electrolytic solutions of storage batteries, secondary batterie...
|
|
WO/2004/072031 |
Compounds of Formula (I): or pharmaceutically acceptable salts thereof, are useful in the prophylactic and therapeutic treatment of hyperglycemia and diabetes.
|
|
WO/2004/071390 |
The present invention is related to piperazine -2-carboxamide derivatives of formula (I) for the treatment and/or prophylaxis of preterm labor, premature birth, dysmenorrhea and for stopping labor prior to cesarean delivery. Wherein A, X...
|
|
WO/2004/069797 |
The invention relates to novel heteroaryl-substituted acetone derivatives, which inhibit the enzyme phospholipase A2, to pharmaceutical agents that contain said compounds and to a method for producing said compounds.
|
|
WO/2004/069846 |
The invention relates to pyrimidines of formula (I), wherein Ln have the meaning indicated in the description while the substituents R1, R2, and R3 have the following meaning: R1 represents C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkinyl, C...
|
|
WO/2004/067537 |
It is intended to provide a compound represented by the following general formula (I) (wherein n represents an integer of 0 or 1; R1 represents hydrogen or alkyl; and A represents an optionally substituted imidazo[2,1-b]thiazole ring) or...
|
|
WO/2004/064764 |
This invention is directed to compounds which are selective antagonists for melanin concentrating hormone-1 (MCH1) receptors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of the compou...
|
|
WO/2004/065381 |
The invention relates to a process for producing a compound of formula (I), wherein a carbazolone of formula II, formaldehyde or a formaldehyde precursor, an amine of formula III or a salt thereof wherein R1 and R2 each independently rep...
|
|
WO/2004/062609 |
Compounds containing the pyrimidine nucleus and their use to treat diseases and conditions related to inappropriate Interleukin-8 receptor activity are disclosed. The compounds are of the formula (I). In these compounds, Q is preferably ...
|
|
WO/2004/060870 |
The present invention relates to compounds of formula (I) wherein R1, R2, R3, R4, R5, R6, m and X are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment . a...
|
|
WO/2004/056784 |
The invention relates to novel substituted carboxamides of general formula (I), in which A, B and R1 to R5 are as defined in claim 1, the tautomers, enantiomers, diastereomers, mixtures and salts thereof, in particular the physiologicall...
|
|
WO/2004/054983 |
The present invention relates to imidazole derivatives of the formula: (I) in which R1, R2, R3, R4, R5, R6 and n are as defined in the specification.The invention also relates to pharmaceutical compositions containing these derivatives, ...
|
|
WO/2004/054991 |
The invention relates to salts consisting of bis(trifluoromethyl)imide anions and saturated, or partially or fully unsaturated heterocyclic cations, to a method for their production and to their use in ionic liquids.
|
|
WO/2004/050610 |
This invention provides compounds and methods for treating melanocortin receptor associated disorders, such as weight loss disorders including cachexia resulting from cancer and other chronic illnesses. The compounds are represented by f...
|
|
WO/2004/048335 |
The invention is concerned with novel mandelic acid derivatives of formula (I), wherein R1 to R10, X and Y are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds inhibit ...
|
|
WO/2004/035567 |
The invention relates to high purity ondansetron hydrochloride dihydrate containing not more than 0.10 w/w % chemical impurities as well as to the process for its synthesis.
|
|
WO/2004/026866 |
This invention relates to N-aroyl cyclic amine derivatives and their use as pharmaceuticals.
|
|
WO/2004/026823 |
The present invention provides estrogen receptor (ER) ligands of structural formula (I) the pharmaceutically acceptable salts, stereoisomers, and prodrugs thereof, and the pharmaceutically acceptable salts of the prodrugs, wherein R1, R2...
|
|
WO/2004/024691 |
Compounds of formula (I) or pharmaceutically acceptable salts thereof are potent and selective inhibitors of COX-2 and are of use in the treatment of the pain, fever and inflammation of a variety of conditions and diseases.
|
|
WO/2004/024699 |
Disclosed are benzimidazolone compounds of formulas (II) wherein X is O, S or NR5. The compounds inhibit production of cytokines involved in inflammatory processes and are thus useful for treating diseases and pathological conditions inv...
|
|
WO/2004/020414 |
This invention relates to compounds of formula (I).
|
|
WO/2004/018485 |
The present invention relates to novel azole derivatives of Formula (I), as potential antifungal agents. This invention also relates to pharmaceutical compositions containing the compounds of the present invention and their use in treati...
|
|
WO/2004/018436 |
The invention relates to novel compounds, the preparation thereof and the uses, particularly therapeutic, of same. More specifically, the invention relates to compounds derived from aryl carbamates, the preparation thereof and the uses o...
|
|
WO/2004/018455 |
New pyrrole based compounds, compositions and methods of inhibiting the activity of glycogen synthase kinase (GSK3) in vitro and of treatment of GSK3 mediated disorders in vivo are provided. The methods, compounds and compositions of the...
|
|
WO/2004/018486 |
The present invention relates to novel azole derivatives of Formula I, as potential antifungal agents.This invention also relates to pharmaceutical compositions containing the compounds of the present invention and their use in treating ...
|
